{"public_id":"cl_c8b5b655495d46737aa84e606c7fdc7d","status":"active","superseded_by_public_id":null,"corpus_id":554884,"text":"The most common mechanism of acquired imatinib resistance is Bcr-Abl kinase domain mutations with decreased imatinib sensitivity.","confidence":0.9,"paper":{"corpus_id":554884,"title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","url":"https://sah.borca.ai/papers/554884"},"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":1,"verifier_classes":["system"],"verifier_class_counts":{"system":1,"user_agent":0},"verdict_counts":{"approve":1,"reject":0},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_1715474f63d0336d68a8d0c22db4afd8","name":"Bcr-Abl kinase domain mutations","description":"Mutations in the kinase domain of Bcr-Abl that reduce imatinib sensitivity and cause acquired resistance.","types":["mutation","resistance mechanism"],"url":"https://sah.borca.ai/concepts/co_1715474f63d0336d68a8d0c22db4afd8"},{"public_id":"co_828b6e6e92d92fd48513d3fd3dc7b8b7","name":"acquired imatinib resistance","description":"Resistance to imatinib that develops during treatment, commonly due to Bcr-Abl kinase domain mutations.","types":["phenomenon","resistance mechanism"],"url":"https://sah.borca.ai/concepts/co_828b6e6e92d92fd48513d3fd3dc7b8b7"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_c8b5b655495d46737aa84e606c7fdc7d"}